

June 19, 2003

**Minutes of the June 19, 2003
Drug Utilization Review (DUR) Board Meeting**

Members Attending: Tim Alford, M.D., Bob Broadus, RPh, Dianna McGowan, RPh, Joe McGuffee, RPh, John Mitchell, M.D., Lee Ann Ramsey, RPh, Sara Weisenberger, M.D., Cynthia Undesser., M.D.

Members Absent: Clarence DuBose, RPh, Andrea Phillips, M.D.

Also Present: Derek Martin, RPh, Lew Anne Snow, RN and Kathleen Burns, RN –HID
Phyllis Williams, Judy Clark, RPh, Gay Gipson, Rica Lewis-Payton – DOM

Dr. Alford called the meeting to order at 2:02 p.m.

Approval of minutes of last meeting (March 20, 2003): Bob Broadus made a motion to accept the minutes as written. John Mitchell seconded the motion. All voted in favor of approval.

Reports:

PA Process:

Lew Anne Snow gave a report on the prior authorization process. This report included numerous steps taken to facilitate the PA process for all Mississippi providers. Also included was an example of a new PA forms developed in an effort to aid providers in completing the request form. Health Information Designs, Inc. will be available to assist providers with the PA process at the Division of Medicaid Provider workshops to be held in August 2003. A draft of the HID newsletter was included as an illustration of ongoing provider education regarding the PA process. It was reported that the prescribing physicians will now be notified by HID when a PA submitted is either approved or denied.

Judy Clark, Pharmacy Bureau Director of the Division of Medicaid, stated that DOM is considering implementing the use of a (9) digit NCD specific PA number to assist pharmacy providers in submission of pharmacy claims.

Pharmacy Program Updates:

Judy Clark, Pharmacy Bureau Director of the Division of Medicaid, reported that effective June 1, 2003, the all Extension of Benefits Prior authorizations will be approved for 12 months. The PDL, with a tiered co-pay system, went into effect in June 2003. Rica Lewis-Payton, Executive Director Division of Medicaid, explained that the PDL is strictly a voluntary list and will remain voluntary as long as DOM sees significant compliance from physicians.

New Business:

Report on Narcotic Prescribing Patterns:

Derek Martin presented a summary of the narcotic prescribing behavior of MS physicians. The study which identified physicians by specialty type, focused on what percentage of all prescriptions written by these providers were narcotics prescriptions. From February 2003 through April 2003, the average narcotic utilization was above the national average of narcotic prescriptions.

Recommendation: Bob Broadus made a motion that HID define criteria for the DUR Board to pursue in identifying physicians and their narcotic prescribing behaviors. Joe McGuffee seconded the motion. All voted in favor of motion.

Black Box Warnings or Boxed Warning Update:

Derek Martin reported on the Black Box warnings issued by the FDA since the last DUR Board meeting in March 2003.

Interventions:

Derek Martin presented intervention recommendations. Each suggested intervention included the number of recipients identified during profile review as being at risk for the specific intervention. These suggested interventions included:

- Black Box Warning concerning ACE Inhibitor Use during Pregnancy
- Therapeutic Duplication of Muscle Relaxants as well as Overutilization of Soma
- Overutilization of Sedative Agents Ambien and Sonata
- Therapeutic Duplication of Atypical Antipsychotics
- The Overutilization of Narcotic Agents
- The Overutilization of Anxiolytic agents
- Therapeutic Duplication of Anxiolytic Agents
- Overutilization of Inhaled Beta-Agonists
- Overutilization of Stimulants

Recommendation: Bob Broadus made a motion to accept all suggested interventions. Montez Carter seconded the motion. All voted in favor of motion

Statistical Report:

Derek Martin presented an Intervention Activity report regarding the intervention letters sent to physicians from January thru March 2003. The report indicated that there were 2769 letters sent to prescribers. The use of the default prescriber number by pharmacies when submitting claims was identified as a continual hindrance in identifying which prescribing physicians should receive an intervention letter.

TREND SUMMARY:

Lew Anne Snow presented a report on all therapeutic drug classes that require prior authorization. The report indicated each drug class by prescription cost and prescription count from January 2002 through March 2003.

DUR Board Members:

Phyllis Williams asked the current members of the DUR Board to consider extending their involvement for one (1) year in an effort facilitate the continuation of ideas and coordination of ongoing thought processes. She explained that this was also proposed to the P&T Committee so that they might continue with their business at hand in an orderly fashion. Those who have concerns with this extension were asked to notify Phyllis Williams.

Next Meeting Information:

Dr Alford reminded the board of the next meeting on September 18, 2003 at 2:00 p.m.

There being no other business, Dr. Alford asked for a motion to adjourn the meeting, Bob Broadus made a motion to adjourn. Montez Carter seconded the motion. All voted in favor of approval. The meeting was then adjourned at 3:22p.m.

Respectfully submitted:
Health Information Designs